RAPS Reports User Fee Reauthorization Bill Advances in the House

“The House Energy and Commerce Committee on Wednesday voted unanimously (54-0) to advance its bill to reauthorize the US Food and Drug Administration’s (FDA) user fee programs for prescription and generic drugs, biosimilars and medical devices to the full House. The committee also adopted several amendments to the version of the bill, known as the FDA Reauthorization Act of 2017, that came out of the health subcommittee on 18 May…  The bill is considered “must-pass” legislation, as failing to reauthorize the user fee agreements before the current ones expire would lead to massive layoffs at FDA.”

Click here for the full story, or here to learn more about how this will affect your complex generic development program and here to contact us.